The BioCentury London and BioCentury Europe indexes each posted double-digit returns in 2012, despite lackluster moves in 4Q12.

The European benchmark was up just 1% last quarter, but ended the year up 42%. Sixteen of 19 continental European biotechs that comprise the market cap-weighted index were up in 2012. Market caps for Swedish Orphan Biovitrum AB (SSE:SOBI) and ThromboGenics N.V. (Euronext:THR) each